Peanut Allergy: Outlook on Global Disease Burden and Therapies (Palforzia)

October 2020 | 51 pages | ID: P430AFFF0C3EEN
BCC Research

Abstracts

Report Scope:

The scope of this report includes an overview on peanut allergy management in comparison with Palforzia.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers of Palforzia immunotherapy.

This report provides a brief explanation of peanut allergy disorder with regional prevalence rates; discusses the different types of diagnostic tests and their applicability in diagnosing various allergens; and provides an overview of the growing immunotherapy market. This report organizes information from diverse sources into a cohesive package that includes -

• A section on diagnostic products such as skin prick tests, specific IgE tests and oral food challenge tests.
• An overview section on guidelines for the prevention of peanut allergy.
• Specific chapters that focus on unmet needs, economic burden, emerging therapies, and regulatory structure.
• A company profiles section that provides background information on companies active in the diagnostic and treatment arenas is also included.

Report Includes:

• An overview of the global market for peanut allergy
• Analysis of current and future market dynamics of peanut allergy market and identification of key drivers, restraints and opportunities
• Coverage of disease background and epidemiology and discussion on disease burden of peanut allergy
• Discussion on technological, regulatory and competitive elements as well as economic trends affecting the future marketplace and pipeline analysis of new products
• Evaluation of current market trends, market size, market forecast and market share analysis of the key companies of the industry and their key market strategies
• Profiles of major players of the industry, including Beckman Coulter Inc., GlaxoSmithKline and Hitachi Chemical Diagnostics Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Methodology
Information Sources
Analyst's Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY

CHAPTER 3 OVERVIEW

Introduction to Peanut Allergy
Etiology and Pathophysiology
Etiology
Pathophysiology
Diagnosis of Peanut Allergy
History
Skin Prick Test (SPT)
Specific IgE (sIgE)
Component-Resolved Diagnosis (CRD)
Oral Food Challenge
The Basophil Activation Test
Epidemiology

CHAPTER 4 UNMET NEEDS

Current Unmet Needs in Managing Peanut Allergies
What We Know
Unmet Needs
Emerging Treatments: Immunotherapies
What We Know
Unmet Needs
Unintentional and Casual Exposures
What We Know
Unmet Needs

CHAPTER 5 THE ECONOMIC IMPACT OF PEANUT ALLERGIES

Burden of Peanut Allergies
Direct Medical and Indirect Costs
Quality of Life
Current and Future Management of Peanut Allergies: Implications for Managed Care
Economic Analysis of Oral Immunotherapy
Barriers to OIT

CHAPTER 6 PALFORZIA: OVERVIEW AND MARKET OUTLOOK

Drug Overview
Scientific Summary
Mechanism of Action
Therapeutic Trials on Safety and Efficacy
Adverse Effects
Dosage, Administration and Cost
Risk Evaluation and Mitigation Strategy
Current Status of PALFORZIA
Regulatory
Commercialization
Market Analysis
Incidence of Peanut Allergy
The Role of Parents
The Role of Allergists
The Role of Payers
Large Addressable Market
Sales Launch Curve

CHAPTER 7 PEANUT ALLERGY PREVENTION GUIDELINES

Australia
U.S. and Canada
Addendum Guideline
Addendum Guideline
Addendum Guideline

CHAPTER 8 EMERGING THERAPIES

Viaskin Peanut: DBV Technologies
Product Description
Clinical and Regulatory Activities
CA002: Camallergy
Product Description
Clinical and Regulatory Activities
PRT100: ProTA Therapeutics
Product Description
Clinical and Regulatory Activities
Dupixent (Dupilumab): Regeneron
Product Description
Clinical and Regulatory Activities

CHAPTER 9 REGULATORY STRUCTURE

Regulations in U.S.
New Drug Approval
The FDA Modernization Act of 1997
Fast Track Status
Special Protocol Assessments
New Surveillance and Safety Requirements
Medicare
Regulations in Europe
Pricing and Reimbursement
Regulations in Japan

CHAPTER 10 COMPANY PROFILES

AIMMUNE THERAPEUTICS INC.
ALERE INC.
ALLERGAN PHARMACEUTICALS
ALK-ABELLO A/S
ALLERGOPHARMA
ANI BIOTECH OY
BECKMAN COULTER/DANAHER
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
GLAXOSMITHKLINE
HITACHI CHEMICAL DIAGNOSTICS INC.
JUBILANT HOLLISTERSTIER
LABORATORY CORP. OF AMERICA HOLDINGS
LINCOLN DIAGNOSTICS INC.
QUEST DIAGNOSTICS
SIEMENS HEALTHCARE
SMARTPRACTICE DENMARK
TARO PHARMACEUTICAL INDUSTRIES
TERUMO MEDICAL CORP.

List Of Tables

LIST OF TABLES

Table 1: Target System Involvement in the Presentation of Peanut Allergy
Table 2: Characteristics of Peanut Allergens
Table 3: Estimated Prevalence of Peanut Allergy Cases in Eight Major Markets, Through 2025
Table 4: Summary of Unmet Needs in Peanut Allergy
Table 5: Direct Medical Costs of Childhood Food Allergy
Table 6: Out-of-Pocket Costs* of Childhood Food Allergy
Table 7: Summary of Addendum Guidelines for Prevention of Peanut Allergy
Table 8: Alere’s Product Portfolio
Table 9: Allergan’s Product Portfolio
Table 10: ALK-Abellу’s Product Portfolio
Table 11: Allergopharma's Product Portfolio
Table 12: Ani Biotech Oy’s Product Portfolio
Table 13: Beckman Coulter’s Product Portfolio
Table 14: Cortez Diagnostics’ Product Portfolio
Table 15: GlaxoSmithKline’s Product Portfolio
Table 16: Hitachi Chemical Diagnostics’ Product Portfolio
Table 17: Jubilant HollisterStier’s Product Portfolio
Table 18: LabCorp’s Product Portfolio
Table 19: Lincoln Diagnostics’ Product Portfolio
Table 20: Quest Diagnostics’ Product Portfolio
Table 21: Siemens Healthcare’s Product Portfolio
Table 22: SmartPractice Denmark’s Product Portfolio
Table 23: Terumo Medical’s Products Portfolio

List Of Figures

LIST OF FIGURES

Figure 1: Pathophysiology of Peanut Allergy
Figure 2: Claim Lines with Diagnoses of Peanut Allergy and Anaphylactic Reaction to Peanuts, by Age Group, 2007-2016